HedgeChatter

  • Home /
  • Tag Archives

OMER

7:08 am Omeros reports additional positive phase 1 clinical data for OMS824 for the treatment of cognitive disorders; PDE10 target engagement continues to increase with well-tolerated doses

moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click here to view […]

February 11, 2014 Bystocknews , Comments Off on 7:08 am Omeros reports additional positive phase 1 clinical data for OMS824 for the treatment of cognitive disorders; PDE10 target engagement continues to increase with well-tolerated doses read more

Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders

[PR Newswire] – SEATTLE, Feb. 11, 2014 /PRNewswire/ — Omeros Corporation (OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros’ phosphodiesterase 10 (PDE10) program. This clinical trial evaluate moreView todays social media effects on OMERView the latest stocks trending across Twitter. Click to view dashboardSee who Omeros is hiring next, click […]

February 11, 2014 Bystocknews , Comments Off on Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders read more